View More View Less
  • 1 Institute of Infectious Diseases, University of Pécs, Hungary
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $784.00

In the past decade, Clostridium difficile infections (CDIs) have become a major public health challenge. Their epidemiology has radically changed with a significant rise in the number of cases and an increase in severe episodes. Recurrence and failure of conventional treatments are very common. Furthermore, a spread of CDI has emerged in general population without the usual risk factors (unexposed to antibiotic treatment, young people, etc.). The conventional treatments (metronidazole and vancomycin) are still effective and are the first-line antibiotics with new recommendations. New therapeutic strategies are now available. Recent studies show a better efficacy of vancomycin compared with metronidazole for severe episodes. Fidaxomicin is a novel antibiotic drug with an efficacy similar to vancomycin and a lower risk of recurrence. Finally, for relapsing forms, fecal microbiota transplantation (FMT) seems to be the best option. We determined risk factors for CDI among patients treated at the infectious diseases ward of our hospital in Pécs. The study included 886 patients with CDI from 2009 to 2014. The average number of recurrent episodes was 2.16 and the proportion of severe cases was 66%. Among our patients, 726 (82%) had taken antibiotics and 769 (86.8%) had been hospitalized in the prior 3 months before developing CDI. We have found that prior statin use could be a significant risk factor of CDI (OR: 1.7765, 95% CI: 1.3966–2.2597, p < 0.0001). Finally, we present the comparative efficacy of different types of treatment (metronidazole, vancomycin, fidaxomicin, and FMT).

  • 1.

    Hall, I. C., O’ Toole, E.: Intestinal flora in newborn infants: With a description of a new pathogenic anaerobe, Bacillus difficile. Am J Dis Child 49, 390 (1935).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Larson, H. E., Price, A. B., Honour, P., Borriello, S. P.: Clostridium difficile and the etiology of pseudo membranous colitis. Lancet 1, 10631066 (1978).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    McDonald, L., Owings, M., Jernigan, D.: Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 12, 409415 (2006).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Lucado, J., Gould, C., Elixhauser, A.: Clostridium difficile infections (CDI) in hospital stays. Statistical brief # 124. Healthcare Cost and Utilization Project. Agency for Healthcare Research and Quality. Available at http://www.hcup-us.ahrq.gov/reports/statbriefs/sb124.pdf (accessed on March 27, 2012).

    • Search Google Scholar
    • Export Citation
  • 5.

    Warny, M., Pepin, J., Fang, A., Kilgore, G. E., Thompson, A., Brazier, J., Frost, E., McDonald, M. C.: Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366, 10791084 (2005).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C., Jr., Kazakova, S. V., Sambol, S. P., Johnson, S., Gerding, D. N.: An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353, 24332441 (2005).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Loo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, M. D., Nguyen, T., Frenette, C., Kelly, M., Vibien, A., Brassard, P., Fenn, S., Dewar, K., Hudson, T. J., Horn, R., René, P., Monczak, Y., Dascal, A.: A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353, 24422449 (2005).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Goudarzi, M., Seyedjavati, S. S., Goudarzi, H., Goudarzi, H., Aghdam, E. M., Nazeri, S.: Clostridium difficile infection: Epidemiology, pathogenesis, risk factors, and therapeutic options. Scientifica 2014, 916826 (2014).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Barbut, F., Jones, G., Eckert, C.: Epidemiology and control of Clostridium difficile infections in healthcare settings: An update. Curr Opin Infect Dis 24, 370376 (2011).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Kuijper, E. J., Barbut, F., Brazier, J. S., Kleinkauf, N., Eckmanns, T., Lambert, M. L., Drudy, D., Fitzpatrick, F., Wiuff, C., Brown, D. J., Coia, J. E., Pituch, H., Reichert, P., Even, J., Mossong, J., Widmer, A. F., Olsen, K. E., Allerberger, F., Notermans, D. W., Delmée, M., Coignard, B., Wilcox, M., Patel, B., Frei, R., Nagy, E., Bouza, E., Marin, M., Akerlund, T., Virolainen-Julkunen, A., Lyytikäinen, O., Kotila, S., Ingebretsen, A., Smyth, B., Rooney, P., Poxton, I. R., Monnet, D. L.: Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill 13, 18942 (2008).

    • Search Google Scholar
    • Export Citation
  • 11.

    Bauer, M. P., Goorhuis, A., Koster, T., Numan-Ruberg, S. C., Hagen, E. C., Debast, S. B., Kuijper, E. J., van Dissel, J. T.: Community-onset Clostridium difficile diarrhoea not associated with antibiotic usage – Two case reports with review of the changing epidemiology of Clostridium difficile-associated diarrhoea. Neth J Med 66, 207211 (2008).

    • Search Google Scholar
    • Export Citation
  • 12.

    Bauer, M. P., Notermans, D. W., van Benthem, B. H. B., Brazier, J. S., Wilcox, M. H., Rupnik, M., Monnet, D. L., van Dissel, J. T., Kuijper, E. J.: Clostridium difficile infection in Europe: A hospital-based survey. Lancet 377, 6373 (2011).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Surawicz, C. M., Brandt, L. J., Binion, D. G., Ananthakrishnan, A. N., Curry, S. R., Gilligan, P. H., McFarland, L. V., Mellow, M., Zuckerbraun, B. S.: Guidelines for diagnoses, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 108, 478498 (2013).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14.

    Vesteinsdottir, I., Gudlaugsdottir, S., Einarsdottir, R., Kalaitzakis, E., Sigurdardottir, O., Bjornsson, E. S.: Risk factors for Clostridium difficile toxin-positive diarrhea: A population-based prospective case-control study. Eur J Clin Microbiol Infect Dis 31, 26012610 (2012).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15.

    Bavishi, C., DuPont, H. L.: Systematic review: The use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 34, 12691281 (2011).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16.

    Deshpande, A., Pant, C., Pasupuleti, V., Rolston, D. D. K., Jain, A., Desphande, N., Thota, P., Sferra, T. J., Hernandez, A. V.: Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol 10, 225233 (2012).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17.

    Janarthanan, S., Ditah, I., Adler, D. G., Ehrinpreis, M. N.: Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: A meta-analysis. Am J Gastroenterol 107, 10011010 (2012).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18.

    Kwok, C. S., Arthur, A. K., Anibueze, C. I., Singh, S., Cavallazzi, R., Loke, Y. K.: Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: Meta-analysis. Am J Gastroenterol 107, 10111019 (2012).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 19.

    Motzkus-Feagans, C. A., Pakyz, A., Polk, R., Gambassi, G., Lapane, K. L.: Statin use and the risk of Clostridium difficile in academic medical centers. Gut 11, 15381542 (2012).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20.

    Naggie, S., Miller, B. A., Zuzak, K. B., Pence, B. W., Mayo, A. J., Nicholson, B. P., Kutty, P. K., McDonald, L. C., Woods, C. W.: A case-control study of community-associated Clostridium difficile infection: No role for proton pump inhibitors. Am J Med 124, 276.e1276.e7 (2011).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 21.

    Park, S. W., Choi, A. R., Lee, H. J., Chung, H., Park, J. C., Shin, S. K., Lee, S. K., Lee, Y. C., Kim, J. E., Lee, H.: The effects of statins on the clinical outcomes of Clostridium difficile infection in hospitalised patients. Aliment Pharmacol Ther 38, 613627 (2013).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 22.

    Saliba, W., Barnett-Griness, O., Elias, M., Rennert, G.: Statins use and risk of mortality in patient with Clostridium difficile infection. Clin Microbiol Infect 20, 10611066 (2014).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 23.

    Elashery, A., Sohi, S., Qi, Y., Chandra, S.: Statin use and hospital-onset Clostridium difficile infection; A case control study. Infect Drug Resist 11, 405416 (2018).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 24.

    McGuire, T., Dobesh, P., Klepser, D., Rupp, M., Olsen, K.: Clinically important interaction between statin drugs and Clostridium difficile toxin? Med Hypotheses 73, 10451047 (2009).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 25.

    Kurti, Zs., Lovasz, B. D., Mandel, M. D., Csima, Z., Golovics, P. A., Csako, B. D., Mohas, A., Gönczi, L., Gecse, K. B., Kiss, L. S., Szathmari, M., Lakatos, P. L.: Burden of Clostridium difficile infection between 2010 and 2013: Trends and outcomes from an academic center in Eastern Europe. World J Gastroenterol 21, 67286735 (2015).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 26.

    Terhes, G., Urban, E., Soki, J., Szikra, L., Konkoly-Thege, M., Vollain, M., Nagy, E.: Assessment of changes in the epidemiology of Clostridium difficile isolated from diarrheal patients in Hungary. Anaerobe 15, 237240 (2009).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 27.

    Nassir Al, W. N., Sethi, A. K., Nerandzic, M. M., Bobulsky, G. S., Jump, R. L. P., Donskey, C. J.: Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis 47, 5662 (2008).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 28.

    Musher, D. M., Aslam, S., Logan, N., Naracheru, S., Bhaila, I., Borchert, F., Hamill, R. J.: Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 40, 15861590 (2005).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 29.

    Debast, S. B., Bauer, M. P., Kuijper, E. J.: Euopean Society of Clinical Microbiology and Infectious Diseases: Update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 20, 126 (2014).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 30.

    Cornely, O. A., Nathwani, D., Ivanescu, C., Odufowora-Sita, O., Retsa, P., Odeyemi, I. A. O.: Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: A meta-analysis and indirect treatment comparison. J Antimicrob Chemother 69, 28922900 (2014).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 31.

    Varier, R. U., Biltaji, E., Smith, K. J., Roberts, M. S., Jensen, M. K., LaFleur, J., Nelson, R. E.: Cost-effectiveness analysis of treatment strategies of Clostridium difficile infection. Clin Microbiol Infect 20, 13431351 (2014).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 32.

    Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., Wilcox, M. H.: Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 31, 431455 (2010).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 33.

    Nagy, G. Gy., Várvölgyi, Cs., Balogh, Z., Orosi, P., Parragh, Gy.: Recommendation for the methodology of fecal transplantation used for treatment of Clostridium difficile associated diarrhea. Orv Hetil 154, 1019 (2013).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 34.

    Vigvari, S., Nemes, Z., Vincze, A, Solt, J., Sipos, D., Feiszt, Z., Kappéter, Á., Kovács, B., Péterfi, Z.: Experience with fecal microbiota transplantation in the treatment of Clostridium difficile infection. Orv Hetil 155, 17581762 (2014).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 35.

    Mitchell, B. G., Gardner, A.: Mortality and Clostridium difficile infection: A review. Antimicrob Resist Infect Control 1, 20 (2012).

 

The author instruction is available in PDF.
Please, download the file from HERE

Senior editors

Editor-in-Chief: Prof. Dóra Szabó (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Managing Editor: Dr. Béla Kocsis (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Co-editor: Dr. Andrea Horváth (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Editorial Board

  • Prof. Éva ÁDÁM (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Sebastian AMYES (Department of Medical Microbiology, University of Edinburgh, Edinburgh, UK.)
  • Dr. Katalin BURIÁN (Institute of Clinical Microbiology University of Szeged, Szeged, Hungary; Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary.)
  • Dr. Orsolya DOBAY (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Ildikó Rita DUNAY (Institute of Inflammation and Neurodegeneration, Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany; Center for Behavioral Brain Sciences (CBBS), Magdeburg, Germany)
  • Prof. Levente EMŐDY(Department of Medical Microbiology and Immunology, University of Pécs, Pécs, Hungary.)
  • Prof. Anna ERDEI (Department of Immunology, Eötvös Loránd University, Budapest, Hungary, MTA-ELTE Immunology Research Group, Eötvös Loránd University, Budapest, Hungary.)
  • Prof. Éva Mária FENYŐ (Division of Medical Microbiology, University of Lund, Lund, Sweden)
  • Prof. László FODOR (Department of Microbiology and Infectious Diseases, University of Veterinary Medicine, Budapest, Hungary)
  • Prof. József KÓNYA (Department of Medical Microbiology, University of Debrecen, Debrecen, Hungary)
  • Prof. Yvette MÁNDI (Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary)
  • Prof. Károly MÁRIALIGETI (Department of Microbiology, Eötvös Loránd University, Budapest, Hungary)
  • Prof. János MINÁROVITS (Department of Oral Biology and Experimental Dental Research, University of Szeged, Szeged, Hungary)
  • Prof. Béla NAGY (Centre for Agricultural Research, Institute for Veterinary Medical Research, Budapest, Hungary.)
  • Prof. István NÁSZ (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Kristóf NÉKÁM (Hospital of the Hospitaller Brothers in Buda, Budapest, Hungary.)
  • Dr. Eszter OSTORHÁZI (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Rozália PUSZTAI (Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary)
  • Prof. Peter L. RÁDY (Department of Dermatology, University of Texas, Houston, Texas, USA)
  • Prof. Éva RAJNAVÖLGYI (Department of Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary)
  • Prof. Ferenc ROZGONYI (Institute of Laboratory Medicine, Semmelweis University, Budapest, Hungary)
  • Prof. Zsuzsanna SCHAFF (2nd Department of Pathology, Semmelweis University, Budapest, Hungary)
  • Prof. Joseph G. SINKOVICS (The Cancer Institute, St. Joseph’s Hospital, Tampa, Florida, USA)
  • Prof. Júlia SZEKERES (Department of Medical Biology, University of Pécs, Pécs, Hungary.)
  • Prof. Mária TAKÁCS (National Reference Laboratory for Viral Zoonoses, National Public Health Center, Budapest, Hungary.)
  • Prof. Edit URBÁN (Department of Medical Microbiology and Immunology University of Pécs, Pécs, Hungary; Institute of Translational Medicine, University of Pécs, Pécs, Hungary.)

 

Editorial Office:
Akadémiai Kiadó Zrt.
Budafoki út 187-187, A/3, H-1117 Budapest, Hungary

Editorial Correspondence:
Acta Microbiologica et Immunologica Hungarica
Institute of Medical Microbiology
Semmelweis University
P.O. Box 370
H-1445 Budapest, Hungary
Phone: + 36 1 459 1500 ext. 56101
Fax: (36 1) 210 2959
E-mail: amih@med.semmelweis-univ.hu

 Indexing and Abstracting Services:

  • Biological Abstracts
  • BIOSIS Previews
  • CAB Abstracts
  • Chemical Abstracts
  • Global Health
  • Index Medicus
  • Index Veterinarius
  • Medline
  • Referativnyi Zhurnal
  • SCOPUS
  • Science Citation Index Expanded

2019  
Total Cites
WoS
485
Impact Factor 1,086
Impact Factor
without
Journal Self Cites
0,864
5 Year
Impact Factor
1,233
Immediacy
Index
0,286
Citable
Items
42
Total
Articles
40
Total
Reviews
2
Cited
Half-Life
5,8
Citing
Half-Life
7,7
Eigenfactor
Score
0,00059
Article Influence
Score
0,246
% Articles
in
Citable Items
95,24
Normalized
Eigenfactor
0,07317
Average
IF
Percentile
7,690
Scimago
H-index
27
Scimago
Journal Rank
0,352
Scopus
Scite Score
320/161=2
Scopus
Scite Score Rank
General Immunology and Microbiology 35/45 (Q4)
Scopus
SNIP
0,492
Acceptance
Rate
16%

 

Acta Microbiologica et Immunologica Hungarica
Publication Model Online only Hybrid
Submission Fee none
Article Processing Charge 1100 EUR/article
Regional discounts on country of the funding agency World Bank Lower-middle-income economies: 50%
World Bank Low-income economies: 100%
Further Discounts Editorial Board / Advisory Board members: 50%
Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100%
Subscription Information Online subsscription: 652 EUR / 812 USD
Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content.
Purchase per Title Individual articles are sold on the displayed price.

Acta Microbiologica et Immunologica Hungarica
Language English
Size A4
Year of
Foundation
1954
Publication
Programme
2021 Volume 68
Volumes
per Year
1
Issues
per Year
4
Founder Magyar Tudományos Akadémia
Founder's
Address
H-1051 Budapest, Hungary, Széchenyi István tér 9.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 1217-8950 (Print)
ISSN 1588-2640 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Jan 2021 15 0 0
Feb 2021 15 1 1
Mar 2021 18 1 1
Apr 2021 4 0 0
May 2021 13 0 0
Jun 2021 7 0 0
Jul 2021 0 0 0